Opus Genetics, Inc. 8-K

What Happened

• Opus Genetics, Inc. announced its financial results for the quarter ended March 31, 2026 and filed an 8-K on May 12, 2026 (Item 2.02: Results of Operations and Financial Condition). The company furnished a press release with the results as Exhibit 99.1, which is incorporated by reference into the filing. The report is signed by Dr. George Magrath, Chief Executive Officer.

Key Details

• Filing date: May 12, 2026 (Form 8-K).
• Reporting period: Quarter ended March 31, 2026 (Q1 2026).
• Press release: Furnished as Exhibit 99.1 to the 8-K.
• Administrative exhibit: Cover Page Interactive Data File embedded as Inline XBRL (Exhibit 104.1).

Why It Matters

• This 8-K notifies investors that Opus Genetics has publicly released its quarterly results — revenue, earnings, cash position, guidance or other material operating metrics (see the furnished press release for specifics).
• Retail investors should read the Exhibit 99.1 press release and review the company’s subsequent filings for the actual financial figures and any commentary on business trends, liquidity, or guidance that could affect the stock.